Rome

• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• ​Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers​ Recruiting
  2024-512442-41-00 9 2024-12-03 Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinom
• Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting
  2023-509673-22-00 9 2024-12-02 Neuroblastoma
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in … Recruiting
  2023-508949-40-00 4 2024-11-29 Eosinophilic esophagitis
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 4 2024-11-27 MMRp/ MSS colon cancer
• Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS Recruiting
  2024-511293-74-01 9 2024-11-26 Refractory Systemic Autoimmune Diseases
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate … Recruiting
  2024-512895-36-00 5 2024-11-25 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma Recruiting
  2024-512113-41-00 5 2024-11-20 Severe Asthma
• A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genet … Recruiting
  2024-513300-34-00 1 2024-11-18 Advanced solid tumors harboring KRAS G12C mutation
• Bomedemstat vs Hydroxyurea for Essential Thrombocythemia Recruiting
  2023-505232-36-00 5 2024-11-15 Essential thrombocythemia
• MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting
  2023-507776-42-00 5 2024-11-14 Non-small cell lung cancer
• NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors Recruiting
  2023-503787-17-00 1 2024-11-13 Solid tumors
• A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe … Recruiting
  2023-508517-16-00 7 2024-11-10 Advanced Solid Tumors with a KRAS p.G12C Mutation
• LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Pa … Recruiting
  2023-507178-41-00 9 2024-11-07 Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD P … Recruiting
  2024-511823-32-00 4 2024-11-06 Duchenne muscular dystrophy (DMD)
• A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia Recruiting
  2023-510288-37-00 3 2024-11-01 Relapsed and/or refractory Acute Myeloid Leukemia

Showing 793–816 of 2,096 trials